Consequently, pharmacological inhibition of HDAC6 could represent an interesting therapeutic strategy in the treatment of myeloproliferative neoplasms, such as polycythemia vera (PV), characterized by the activating mutation JAK2V617F. The gene discussed is HDAC6; the disease is myeloproliferative neoplasm.